Thalidomide: Current Therapeutic Uses and Management of Its Toxicities | Zendy

Joseph D Tariman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Thalidomide: Current Therapeutic Uses and Management of Its Toxicities

Author(s) -

Joseph D Tariman

Publication year - 2003

Publication title -

clinical journal of oncology nursing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.375

H-Index - 43

eISSN - 1538-067X

pISSN - 1092-1095

DOI - 10.1188/03.cjon.143-147

Subject(s) - thalidomide , medicine , multiple myeloma , intensive care medicine , clinical trial , drug , refractory (planetary science) , pharmacology , physics , astrobiology

Thalidomide currently is used to treat relapsed and refractory multiple myeloma. The drug also is being actively investigated in patients newly diagnosed with multiple myeloma. The therapeutic applications of thalidomide are expected to grow as clinical trials document its activity in treating other neoplastic disorders and diseases. Healthcare providers need to be well informed of its toxicities and able to identify their signs and symptoms immediately. They must have adequate knowledge about thalidomide administration and provide comprehensive patient education regarding thalidomide and its toxicities to ensure patient safety and compliance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research